# Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).

> **NCT02045212** · PHASE2 · COMPLETED · sponsor: **Regenera Pharma Ltd** · enrollment: 22 (actual)

## Conditions studied

- Non-arteritic Ischemic Optic Neuropathy
- Optic Nerve Injuries

## Interventions

- **DRUG:** RPh201
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02045212
- **Lead sponsor:** Regenera Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-08
- **Final completion:** 2016-12
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045212, "Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02045212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*